Top

Osteoporosis International

Published in:

01-08-2010 | Original Article

Increased serum osteopontin is a risk factor for osteoporosis in menopausal women

Authors: I.-C. Chang, T.-I. Chiang, K.-T. Yeh, H. Lee, Y.-W. Cheng

Published in: Osteoporosis International | Issue 8/2010

Abstract

Summary

Osteopontin (OPN)-deficient mice are resistant to ovariectomy-induced osteoporosis. Therefore, we hypothesized that women with OPN overexpression may show less resistance to postmenopausal osteoporosis. In this study, we first demonstrated that serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.

Introduction

Animal studies indicate that OPN-deficient mice are resistant to ovariectomy-induced osteoporosis.

Methods

From 2004 to 2006, 124 women over the age of 45 were enrolled in a menopausal group, while another 95 women, from 25 to 45 years of age with regular menstruation, were enrolled into a childbearing age group. The serum concentrations of OPN were calculated using the enzyme-link immunosorbent assay method, and bone mineral densities were determined with dual energy X-ray absorptiometry.

Results

Serum OPN levels had a significant positive correlation with age (menopausal group, p < 0.0001) and a negative correlation with body weight, height, hip bone mineral density, and T-scores in the menopausal group. In contrast, there was a positive correlation with the E2 concentration and height, but there was no significant association with the above variables in the childbearing age group. Additionally, high serum OPN levels (>14.7 ng/ml) was a significant risk factor causing menopausal osteoporosis (odds ratio = 2.96, 95% confidence interval, 1.055–8.345).

Conclusion

Serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.

Ishijima M, Ezura Y, Kunikazu T, Rittling SR, Kurosawa H, Denhardt DT, Emi M, Nifuji A, Noda M (2006) Osteopontin during tail-suspension-induced bone loss. Exp Cell Res 312:3075–3083CrossRefPubMed

Rittling SR, Matsumoto HN, Mckee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101–1111CrossRefPubMed

Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113CrossRefPubMed

Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 96:8156–8160CrossRefPubMed

Asou Y, Rittling SR, Yoshitake H, Tsuji K, Shinomiya K, Nifuji A, Denhardt DT, Noda M (2001) Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142:1325–1332CrossRefPubMed

Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M (2001) Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276:13065–13071CrossRefPubMed

Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M (2002) Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A 99:4556–4561CrossRefPubMed

Morinobu M, Ishijima M, Rittling SR, Tsuji K, Yamamoto H, Nifuji A, Denhardt DT, Noda M (2003) Osteopontin expression in osteoblasts and osteocytes during bone formation under mechanical stress in the calvarial suture in vivo. J Bone Miner Res 18:1706–1715CrossRefPubMed

Kitahara K, Ishijima M, Rittling SR, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2003) Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144:2132–2140CrossRefPubMed

10.

Chen Y, Bal BS, Gorski JP (1992) Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 267:24871–24878PubMed

11.

Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265CrossRefPubMed

12.

MacNeli RL, Berry J, D'ErricoJ SC, Piotrowski B, Somerman MJ (1995) Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. Connect Tissue Res 33:1–7CrossRef

13.

Horton MA, Nesbit MA, Helfrich MH (1995) Interaction of osteopontin with osteoclast integrins. Ann N Y Acad Sci 760:190–200CrossRefPubMed

14.

Giachelli CM, Liaw L, Murry CE, Schwartz S, Almeida MM (1995) Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 760:109–126CrossRefPubMed

15.

Liaw L, Lombardi DM, Almeida MM, Schwartz SM, DeBlois D, Giachelli CM (1997) Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 17:188–193PubMed

16.

Pichler R, Giachelli CM, Young B, Alpers CE, Couser WG, Johnson RJ (1995) The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Miner Electrolyte Metab 21:317–327PubMed

17.

Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L (1995) Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci 760:83–100CrossRefPubMed

18.

Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509–512CrossRefPubMed

19.

Kennedy OD, Brennan O, Rackard SM, Staines A, O'Brien FJ, Taylor D, Lee TC (2009) Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J Orthop Res 27:303–309CrossRefPubMed

20.

Shapses SA, Cifuentes M, Spevak L, Chowdhury H, Brittingham J, Boskey AL, Denhardt DT (2003) Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calcif Tissue Int 73(1):86–92CrossRefPubMed

21.

Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Ezura Y, Noda M (2007) Osteopontin is required for mechanical stress-dependent signals to bone marrow cells. J Endocrinol 193(2):235–243CrossRefPubMed

22.

Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB (2007) Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res 83(1):136–144CrossRef

23.

McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393CrossRefPubMed

24.

Malaval L, Wade-Guéye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amédée J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205(5):1145–1153CrossRefPubMed

25.

Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 31:92–102CrossRef

26.

Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodeling rather than in inflammation in ankylosing spondylitis. Rheumatology 47:1775–1779CrossRefPubMed

27.

Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9(1):59–67PubMed

28.

Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer. Lancet Oncol 6:757–764CrossRefPubMed

29.

Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, Dunst J, Flentije M, Bache M (2006) Plasma osteopontin lecels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 207:1–6

30.

Eastell R (2003) Pathogenesis of postmenopausal osteoporosis. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. American Society for Bone and Mineral Research, Washington (DC), pp 314–316

31.

Recker R, Lappe J, Davies K, Heaney R (2000) Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 15:1965–1973CrossRefPubMed

32.

Abrahamsen B, Nissen N, Hermann AP, Hansen B, Bärenholdt O, Vestergaard P, Tofteng CL, Pors Nielsen S (2002) When should densitometry be repeated in healthy peri- and postmenopausal women? The Danish osteoporosis prevention study. J Bone Miner Res 17:2061–2067CrossRefPubMed

33.

Li Y, Li A, Yang X, Weitzmann MN (2007) Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100(6):1370–1375CrossRefPubMed

34.

Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J (2002) Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 17(8):1486–1497CrossRefPubMed

35.

Rajachar RM, Truong AQ, Giachelli CM (2008) The influence of surface mineral and osteopontin on the formation and function of murine bone marrow-derived osteoclasts. J Mater Sci Mater Med 19(10):3279–3285CrossRefPubMed

36.

Ono N, Nakashima K, Rittling SR, Schipani E, Hayata T, Soma K, Denhardt DT, Kronenberg HM, Ezura Y, Noda M (2008) Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem 283(28):19400–19409CrossRefPubMed

37.

Namkung-Matthai H, Appleyard R, Jansen J (2001) Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. Bone 28:80–86CrossRefPubMed

38.

Roseleen M, McCann GC, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393CrossRef

39.

D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G (2006) Receptor activator of NF (Kappa) B ligand/osteoprotegerin (RANKL/OPG) system and osteoportnin (OPN) serum levels in a population of apullian postmenopausal women. Panminerva Med 48(4):215–221PubMed

40.

Vondracek SF, Hansen LB, McDermott MT (2009) Osteoporosis risk in premenopausal women. Pharmacotherapy 29(3):305–317CrossRefPubMed

41.

Bischoff L, Derk CT (2008) Premenopausal osteoporosis. Minerva Med 99(1):55–63PubMed

42.

Hamel ME, Sebaldt RJ, Siminoski K, Adachi JD, Papadimitropoulos AP, Goldsmith CH (2005) Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. Osteoporos Int 16:208–215CrossRefPubMed

43.

Solomon DH, Levin E, Helfgott SM (2000) Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. J Rheumatol 27:1496–1500PubMed

44.

Pressman A, Forsyth B, Ettinger B, Tosteson ANA (2001) Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int 12:337–342CrossRefPubMed

45.

Hajcsar EE, Hawker G, Bogoch ER (2000) Investigation and treatment of osteoporosis in patients with fragility fractures. Can Med Assoc J 163:819–822

46.

Ridout R, Hawker GA (2000) Use of bone densitometry by Ontario family physicians. Osteoporos Int 11:393–399CrossRefPubMed

47.

Papa LJ, Weber BE (1997) Physician characteristics associated with the use of bone densitometry. J Gen Intern Med 12:781–783CrossRefPubMed

Title: Increased serum osteopontin is a risk factor for osteoporosis in menopausal women
Authors: I.-C. Chang
T.-I. Chiang
K.-T. Yeh
H. Lee
Y.-W. Cheng
Publication date: 01-08-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-1107-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased serum osteopontin is a risk factor for osteoporosis in menopausal women

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2010

International comparison of cost of falls in older adults living in the community: a systematic review

The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis

Erratum to: Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in Caucasians

Adjustment for body mass index and calcitrophic hormone levels improves the diagnostic accuracy of the spot urine calcium-to-creatinine ratio

A paediatric bone index derived by automated radiogrammetry

Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans